FibroBiologics Files 8-K on Equity Sales
Ticker: FBLG · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1958777
Sentiment: neutral
Topics: equity-sale, filing
TL;DR
FibroBiologics sold unregistered equity, check for dilution.
AI Summary
On January 7, 2025, FibroBiologics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also included financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Houston, Texas.
Why It Matters
This filing indicates potential dilution for existing shareholders due to the unregistered sale of equity securities.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can lead to dilution and potential regulatory scrutiny.
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- January 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal executive offices
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type of securities in the provided text.
Were these securities sold to accredited investors?
The filing mentions 'Unregistered Sales of Equity Securities,' which often implies sales to accredited investors to comply with exemptions from registration, but this specific detail is not explicitly stated in the provided text.
What is the total number of shares sold and the price per share?
The provided text does not contain specific details on the number of shares sold or the price per share.
What is the purpose of these unregistered equity sales?
The purpose of the unregistered equity sales is not detailed in the provided text of the 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 7, 2025.
Filing Stats: 822 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2025-02-07 17:24:41
Key Financial Figures
- $0.00001 — ichregistered Common stock, par value $0.00001 per share FBLG Nasdaq Global Marke
- $15 million — forth therein, the principal amount of $15 million (the "Pre-Paid Advance"), which will be
- $250,000 — the Investor a commitment fee totaling $250,000 (the "Commitment Fee"). On December 20,
- $5.0 million — the Investor in the principal amount of $5.0 million. On December 30, 2024, the second tranc
- $2.1010 — e "Common Stock"), to the Investor at a $2.1010 price per share. On January 23, 2025,
- $900,000 — anuary 23, 2025, the Investor converted $900,000 in principal amount of the Second Note
- $1.6301 — tor 552,113 shares of Common Stock at a $1.6301 conversion price per share. On Januar
- $500,000 — anuary 27, 2025, the Investor converted $500,000 in principal amount of the Second Note
- $1.5761 — tor 317,238 shares of Common Stock at a $1.5761 conversion price per share. On Januar
- $1.4955 — tor 334,336 shares of Common Stock at a $1.4955 conversion price per share. On Februa
- $1,100,000 — ebruary 7, 2025, the Investor converted $1,100,000 in principal amount of the Second Note
- $1.5008 — tor 732,941 shares of Common Stock at a $1.5008 conversion price per share. The Secon
- $2.0 million — te has a remaining principal balance of $2.0 million. The sale of the securities listed in
Filing Documents
- form8-k.htm (8-K) — 42KB
- 0001493152-25-005456.txt ( ) — 214KB
- fblg-20250107.xsd (EX-101.SCH) — 3KB
- fblg-20250107_lab.xml (EX-101.LAB) — 33KB
- fblg-20250107_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: February 7, 2025 FibroBiologics, Inc. By: /s/ Pete O'Heeron Name: Pete O'Heeron Title: Chief Executive Officer